Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes.

Plain-language guide to PMID 18381573 (2008): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 63 men.

Key Facts

PMID: 18381573
Journal: The Journal of clinical endocrinology and metabolism
Year: 2008
Study type: Randomized Controlled Trial
Authors: Nelson AE et al. (12 authors)
DOI: 10.1210/jc.2008-0402

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Their objective was to investigate whether responses of serum IGF axis and collagen markers to GH differ between men and women, and are influenced by testosterone (T).

Who Took Part

The study group was 63 men.

The age groups tagged for this paper are teenagers and adults, both men and women.

This was a randomized, double-blind, placebo-controlled study of 8-wk treatment followed by 6-wk washout.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Blinding on both sides kept the men and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some men received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The study was performed at a clinical research facility.

What Was Measured

The subject headings attached to it are Carrier Proteins, Collagen, Glycoproteins, Gonadal Steroid Hormones, Growth Hormone, Insulin-Like Growth Factor Binding Protein 3 and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 63 men.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.